Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | BUB1 | O43683 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11265654 | 0.75 | BRD4 (0.61) | KMT2AL3MBTL1BRD4BUB1DYRK1A | |
| SCHEMBL29824193 | 0.72 | PARP1 (0.59) | MAPTKMT2AL3MBTL1BRD4KDM4E | |
| SCHEMBL23537356 | 0.72 | PARP1 (0.59) | MAPTKMT2AL3MBTL1BRD4KDM4E | |
| SCHEMBL9803050 | 0.72 | L3MBTL1 (0.48) | MAPTKMT2AL3MBTL1BRD4KDM4E | |
| SCHEMBL29824409 | 0.69 | PARP1 (0.64) | KMT2AL3MBTL1BRD4KDM4EBUB1 | |
| SCHEMBL23537328 | 0.69 | PARP1 (0.64) | KMT2AL3MBTL1BRD4KDM4EBUB1 | |
| SCHEMBL19952820 | 0.67 | PARP1 (0.44) | MAPTKMT2ABRD4KDM4E | |
| SCHEMBL31027151 | 0.66 | DYRK1A (0.58) | MAPTKMT2AKDM4EDYRK1A | |
| SCHEMBL4455323 | 0.66 | MAPT (1.00) | MAPTKMT2AKDM4E | |
| SCHEMBL2220752 | 0.66 | DYRK1A (0.58) | MAPTKMT2AKDM4EDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| WO-2007089634-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | FASN, FADS2, FADS1 | MAPT 4736/4885KMT2A 1811/4885L3MBTL1 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.